EDITORIAL Should addiction researchers be interested in psychedelic science ? Stephen Bright, Martin Williams & David Caldicott Australasian Professional Society on Alcohol and other Drugs, Drug and Alcohol Review, 2017 DOI: 10.1111/dar.12544 As recently noted by Strauss, Bright and Williams [1], while much of the Western world has been experiencing a renaissance in research into ‘psychedelic science’ over the past decade [2], there has been no such research conducted in Australia. In Europe and the USA, studies have been conducted into lysergic acid diethylamide (LSD) that have improved our understanding of brain function [3] and reduced existential anxiety associated with dying [4], while psilocybin-assisted psychotherapy has [...]
Lire la suiteThe psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion JAMILAH R. GEORGE, TIMOTHY I. MICHAELS, JAE SEVELIUS and MONNICA T. WILLIAMS Journal of Psychedelic Studies, 2019 DOI: 10.1556/2054.2019.015 In recent years, the study of psychedelic science has resurfaced as scientists and therapists are again exploring its potential to treat an array of psychiatric conditions, such as depression, post-traumatic stress disorder, and addiction. The scientific progress and clinical promise of this movement owes much of its success to the history of indigenous healing practices; yet the work of indigenous people, ethnic and racial minorities, women, [...]
Lire la suitePsychological variables implied in the therapeutic effect of ayahuasca : a contextual approach. Alba Franquesa, Alberto Sainz-Cort, Sam Gandy, Joaquim Soler, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso Psychiatry Research, 2017 PII: S0165-1781(17)31377-X DOI: 10.1016/j.psychres.2018.04.012 Abstract Ayahuasca is a psychedelic decoction originating from Amazonia. The ayahuasca-induced introspective experience has been shown to have potential benefits in the treatment of several pathologies, to protect mental health and to improve neuropsychological functions and creativity, and boost mindfulness. The underlying psychological processes related to the use of ayahuasca in a psychotherapeutic context are not yet well described in the scientific literature, but there is some evidence to suggest that psychological [...]
Lire la suiteAyahuasca : Uses, Phytochemical and Biological Activities, Edgar Antonio Estrella‑Parra et al., 2019
Ayahuasca : Uses, Phytochemical and Biological Activities Edgar Antonio Estrella‑Parra, · Julio Cesar Almanza‑Pérez, · Francisco Javier Alarcón‑Aguilar Natural Products and Bioprospecting, 2019 https://doi.org/10.1007/s13659-019-0210-5 Abstract Ayahuasca (caapi, yajé), is a psychoactive brew from the Amazon Basin region of South America traditionally considered a “master plant.” It is prepared as a decoction from Banisteriopsis caapi and Psychotria viridis, which it is thought that it stimulates creative thinking and visual creativity. Native healers of the Orinoco and Amazon basins have used traditionally ayahuasca as a healing tool for multiple purposes, particularly to treat psychological disorders in the patients, with some beneficial effects experimentally and clinically validated. Recently, [...]
Lire la suiteFour Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities : A Comparison Study With a Standard 8-Week Mindfulness Training Program Joaquim Soler, Matilde Elices, Elisabeth Dominguez-Clavé, Juan C. Pascual, Amanda Feilding, Mayte Navarro-Gil, Javier García-Campayo and Jordi Riba Frontiers in Pharmacology, 2018, 9, 224. doi: 10.3389/fphar.2018.00224 Background : The therapeutic effects of the Amazonian plant tea ayahuasca may relate to its ability to enhance mindfulness capacities. Ayahuasca induces a modified state of awareness through the combined action of its active principles: the psychedelic N,N-dimethyltryptamine (DMT) and a series of centrally acting b-carbolines, mainly harmine and tetrahydroharmine. To better understand the therapeutic potential of [...]
Lire la suiteLSD helps to treat alcoholism Retrospective analysis shows hallucinogenic drug helped problem drinkers. Arran Frood Nature, 09 March 2012 doi : 10.1038/nature.2012.10200 Rights & Permissions DEA/Science Faction/Corbis An analysis of old studies suggests LSD may have a role to play in treating alcoholism. The powerful hallucinogen LSD (lysergic acid diethylamide) has potential as a treatment for alcoholism, according to a retrospective analysis of studies published in the late 1960s and early 1970s. The study1, by neuroscientist Teri Krebs and clinical psychologist Pål-Ørjan Johansen of the Norwegian University of Science and Technology in Trondheim, is the first-ever quantitative meta-analysis of LSD–alcoholism clinical trials. The researchers sifted through [...]
Lire la suiteLa psychothérapie psychédélique est de retour M le magazine du Monde | 12.03.2015 Mescaline, ecstasy, psilocybine soigneront-ils la dépression, l’angoisse, l’autisme ou l’alcoolisme ? Des psychiatres américains explorent le potentiel thérapeutique de ces substances illicites. Par Stéphanie Chayet Engourdissement, d’abord. Puis grande fatigue, bâillements. Des images, très abstraites, comme de l’art moderne. Des motifs. Image d’un chat en train de mordiller le câble de freinage d’un vélo. Après ça ? Sentiment de ne pas m’aimer. Pas du tout. Puis je me demande : pourquoi je ne m’aimerais pas ? Il n’y a aucune raison. » Ainsi commence, mot pour mot, le « compte rendu d’expérience [...]
Lire la suiteDu LSD ou de l’ecstasy pour traiter la maladie mentale La thérapie psychédélique a pour principe d’aider les gens à adopter un nouveau regard sur leur santé et leur mode de vie. Alexis Riopel 10 décembre 2018 https://www.ledevoir.com/societe/sante/543271/science-du-lsd-ou-de-l-ecstasy-pour-traiter-la-maladie-mentale Un cachet, une séance, des effets qui perdurent. Grosso modo, telle est la promesse des psychiatres qui travaillent sur le développement de traitements recourant à des drogues psychédéliques pour soigner des troubles de santé mentale. Plutôt que d’apaiser les symptômes de la maladie mentale, ces substances servent à « reconnecter » le cerveau. Si elles étaient légalisées dans un contexte médical — et c’est ce qui semble en [...]
Lire la suiteA Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy Ben Sessa, Laurie Higbed and David Nutt Frontiers in Psychiatry, 2019, Vol. 10, article 138 DOI : 10.3389/fpsyt.2019.00138 Neuropsychopharmacology Unit, Department of Medicine, Imperial College London, London, United Kingdom Abstract : This paper provides a brief review of the history, proposed pharmacological mechanisms, safety issues, and clinical applications of the medicine 3,4-methylenedioxymethamphetamine (MDMA). Most clinical MDMA research in patients to date has focused on MDMA-assisted psychotherapy to treat posttraumatic stress disorder (PTSD). In this review paper other potential therapeutic applications for MDMA therapy are described, including contemporary studies treating anxiety associated with autism and the authors’ ongoing study exploring the potential [...]
Lire la suiteDark Classics in chemical Neuroscience : Lysergic Acid Diethylamide (LSD), David E. Nichols, ACS Chemical Neuroscience, 2018, 9, 10, 2331-2334. doi: 10.1021/acschemneuro.8b00043. Abstract : LSD is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 g) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led [...]
Lire la suite